# VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

> **NCT03015181** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 26 (actual)

## Conditions studied

- HIV Prevention

## Interventions

- **BIOLOGICAL:** VRC-HIVMAB075-00-AB

## Key facts

- **NCT ID:** NCT03015181
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-21
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-07-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03015181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03015181, "VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03015181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*